NasdaqCM - Nasdaq Real Time Price USD

Alterity Therapeutics Limited (ATHE)

Compare
3.4900 +0.0400 (+1.16%)
At close: January 21 at 4:00:02 p.m. EST
3.4000 -0.09 (-2.58%)
After hours: January 21 at 5:30:35 p.m. EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ATHE

Recent News: ATHE

View More
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
GlobeNewswire 12 days ago
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
GlobeNewswire last month
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
GlobeNewswire 2 months ago
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
GlobeNewswire 2 months ago
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
GlobeNewswire 2 months ago
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
GlobeNewswire 2 months ago
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
GlobeNewswire 3 months ago
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
GlobeNewswire 3 months ago
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire 3 months ago
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
GlobeNewswire 3 months ago
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire 3 months ago
View More

Related Tickers

XBIO Xenetic Biosciences, Inc.
4.3199
+1.88%
 
GLSI Greenwich LifeSciences, Inc.
12.16
-5.52%
 
IMRN Immuron Limited
2.3391
+6.81%
 
KTTA Pasithea Therapeutics Corp.
2.5250
+1.81%
 
ADIL Adial Pharmaceuticals, Inc.
0.9725
-1.77%
 
SONN Sonnet BioTherapeutics Holdings, Inc.
1.5400
0.00%
 
STOK Stoke Therapeutics, Inc.
9.80
+4.70%
 
LIXT Lixte Biotechnology Holdings, Inc.
2.3835
+2.30%
 
VTVT vTv Therapeutics Inc.
13.97
+2.38%
 
ACIU AC Immune SA
2.6500
-1.12%